TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis
NASDAQ:TGTX - Nasdaq - US88322Q1085 - Common Stock - Currency: USD
TGTX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. TGTX has only an average score on both its financial health and profitability. TGTX is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
TGTX had positive earnings in the past year.
In the past year TGTX has reported a negative cash flow from operations.
In multiple years TGTX reported negative net income over the last 5 years.
In the past 5 years TGTX always reported negative operating cash flow.
1.2 Ratios
TGTX's Return On Assets of 5.96% is amongst the best of the industry. TGTX outperforms 93.05% of its industry peers.
The Return On Equity of TGTX (16.50%) is better than 95.54% of its industry peers.
With an excellent Return On Invested Capital value of 9.52%, TGTX belongs to the best of the industry, outperforming 94.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.96% | ||
| ROE | 16.5% | ||
| ROIC | 9.52% |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TGTX has a Profit Margin of 10.13%. This is amongst the best in the industry. TGTX outperforms 93.05% of its industry peers.
TGTX has a better Operating Margin (15.48%) than 94.83% of its industry peers.
TGTX has a Gross Margin of 87.43%. This is amongst the best in the industry. TGTX outperforms 89.30% of its industry peers.
In the last couple of years the Gross Margin of TGTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.48% | ||
| PM (TTM) | 10.13% | ||
| GM | 87.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TGTX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
The number of shares outstanding for TGTX has been increased compared to 5 years ago.
Compared to 1 year ago, TGTX has a worse debt to assets ratio.
2.2 Solvency
TGTX has an Altman-Z score of 6.22. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of TGTX (6.22) is better than 82.17% of its industry peers.
A Debt/Equity ratio of 1.03 is on the high side and indicates that TGTX has dependencies on debt financing.
The Debt to Equity ratio of TGTX (1.03) is worse than 78.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.22 |
ROIC/WACC0.94
WACC10.1%
2.3 Liquidity
A Current Ratio of 4.02 indicates that TGTX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.02, TGTX is in line with its industry, outperforming 47.24% of the companies in the same industry.
TGTX has a Quick Ratio of 3.04. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX has a Quick ratio of 3.04. This is in the lower half of the industry: TGTX underperforms 62.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.02 | ||
| Quick Ratio | 3.04 |
3. Growth
3.1 Past
TGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.09%, which is quite good.
Looking at the last year, TGTX shows a very strong growth in Revenue. The Revenue has grown by 33.54%.
Measured over the past years, TGTX shows a very strong growth in Revenue. The Revenue has been growing by 364.59% on average per year.
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%142.86%
Revenue 1Y (TTM)33.54%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%90.4%
3.2 Future
The Earnings Per Share is expected to grow by 103.07% on average over the next years. This is a very strong growth
Based on estimates for the next years, TGTX will show a very strong growth in Revenue. The Revenue will grow by 37.10% on average per year.
EPS Next Y523.66%
EPS Next 2Y264.81%
EPS Next 3Y161.7%
EPS Next 5Y103.07%
Revenue Next Year86.57%
Revenue Next 2Y60.72%
Revenue Next 3Y47.96%
Revenue Next 5Y37.1%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
TGTX is valuated quite expensively with a Price/Earnings ratio of 144.04.
91.09% of the companies in the same industry are more expensive than TGTX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.82, TGTX is valued quite expensively.
Based on the Price/Forward Earnings ratio of 18.55, the valuation of TGTX can be described as rather expensive.
92.69% of the companies in the same industry are more expensive than TGTX, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.76. TGTX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 144.04 | ||
| Fwd PE | 18.55 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TGTX indicates a rather cheap valuation: TGTX is cheaper than 91.44% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 86.9 |
4.3 Compensation for Growth
TGTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TGTX has a very decent profitability rating, which may justify a higher PE ratio.
TGTX's earnings are expected to grow with 161.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y264.81%
EPS Next 3Y161.7%
5. Dividend
5.1 Amount
TGTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
34.57
+0.33 (+0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners63.58%
Inst Owner Change3.04%
Ins Owners10.03%
Ins Owner Change3.19%
Market Cap5.43B
Analysts80
Price Target43.35 (25.4%)
Short Float %16.33%
Short Ratio6.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.32%
Min EPS beat(2)-83.83%
Max EPS beat(2)77.18%
EPS beat(4)2
Avg EPS beat(4)36.4%
Min EPS beat(4)-83.83%
Max EPS beat(4)185.79%
EPS beat(8)4
Avg EPS beat(8)67.99%
EPS beat(12)7
Avg EPS beat(12)49.15%
EPS beat(16)8
Avg EPS beat(16)35.54%
Revenue beat(2)2
Avg Revenue beat(2)3.08%
Min Revenue beat(2)0.05%
Max Revenue beat(2)6.12%
Revenue beat(4)4
Avg Revenue beat(4)4.03%
Min Revenue beat(4)0.05%
Max Revenue beat(4)9.31%
Revenue beat(8)7
Avg Revenue beat(8)34.64%
Revenue beat(12)9
Avg Revenue beat(12)33.86%
Revenue beat(16)10
Avg Revenue beat(16)19.61%
PT rev (1m)0.17%
PT rev (3m)3.98%
EPS NQ rev (1m)-9.29%
EPS NQ rev (3m)-4%
EPS NY rev (1m)-7.96%
EPS NY rev (3m)-1.98%
Revenue NQ rev (1m)1.54%
Revenue NQ rev (3m)12.32%
Revenue NY rev (1m)5.47%
Revenue NY rev (3m)8.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 144.04 | ||
| Fwd PE | 18.55 | ||
| P/S | 14.05 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 22.88 | ||
| P/tB | 22.88 | ||
| EV/EBITDA | 86.9 |
EPS(TTM)0.24
EY0.69%
EPS(NY)1.86
Fwd EY5.39%
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS2.46
BVpS1.51
TBVpS1.51
PEG (NY)0.28
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.96% | ||
| ROE | 16.5% | ||
| ROCE | 12.05% | ||
| ROIC | 9.52% | ||
| ROICexc | 21.46% | ||
| ROICexgc | 21.46% | ||
| OM | 15.48% | ||
| PM (TTM) | 10.13% | ||
| GM | 87.43% | ||
| FCFM | N/A |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score3
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.09 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 2.7 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.02 | ||
| Quick Ratio | 3.04 | ||
| Altman-Z | 6.22 |
F-Score3
WACC10.1%
ROIC/WACC0.94
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%142.86%
EPS Next Y523.66%
EPS Next 2Y264.81%
EPS Next 3Y161.7%
EPS Next 5Y103.07%
Revenue 1Y (TTM)33.54%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%90.4%
Revenue Next Year86.57%
Revenue Next 2Y60.72%
Revenue Next 3Y47.96%
Revenue Next 5Y37.1%
EBIT growth 1Y23.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year584.73%
EBIT Next 3Y125.12%
EBIT Next 5YN/A
FCF growth 1Y63.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.54%
OCF growth 3YN/A
OCF growth 5YN/A